AVE LAUNCHES MICRO STENT II, SLATES GFX SHIPMENTS FOR MARCH FOLLOWING DEC. 23 FDA APPROVAL; RAPID EXCHANGE DELIVERY SYSTEM IN CLINICALS
This article was originally published in The Gray Sheet
Executive Summary
Arterial Vascular Engineering is planning to launch its Micro Stent II and gfx coronary stent systems in two phases following premarket approval application clearance by FDA on Dec. 23, the company says. Shipments of the Micro Stent II will commence immediately while roll out of the gfx is scheduled for March following inventory ramp up.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.